Studies on the interference of ganciclovir to HCV liver fibrosis.
To investigate the significance of the combined treatment with ganciclovir and interferon for patients with hepatitis C (HCV) liver fibrosis.



We retrospectively summarize 86 patients with hepatitis C treated in our hospital from October 2013 to October 2015. 49 cases, considered as control group, received combined treatment with α-interferon and ribavirin; 37 cases, considered as observation group, received combined treatment with ganciclovir and interferon. The changes of liver fibrosis, viral replication and liver function of both groups were compared for two weeks and six months.



The levels of sera hyaluronic acid (HA), laminin (LN), type IV collagen (IVC) and type III procollagen (PIII NP) of both groups were reduced after treatment, and the observation group improved more significantly (p <0.05). Compared to the rate of antigen-positive after treatment and HCV copy number before and after treatment, the differences were not statistically significant (p > 0.05). The level of alanine aminotransferase (ALT) of the control group increased after treatment, compared with that before. This was done along with the decrease of the level of albumin. By contrast, the level of ALT in the observation group was reduced and the level of albumin was increased compared with that before (p < 0.05).



Ganciclovir combined with interferon may further reduce the fibrosis process of patients with hepatitis C, and may improve liver function. The effect of antiviral was similar as ganciclovir combined with Interferon was comparatively good applied, safety and effectiveness.
Department of Infectious Disease, The Second Affiliated Hospital and Yuying Children' Hospital of Wenzhou Medical University, Wenzhou City, Zhejiang Province, China. zhengyi20160628@163.com.
J
J
Li
C-W
CW
Pan
G-Y
GY
Zhou
L
L
Zhuge
P-P
PP
Fang
L-X
LX
Jin
W
W
Lin
X-Z
XZ
Lin
Y
Y
Zheng
D000998:Antiviral Agents / Q000627:therapeutic use*; D015774:Ganciclovir / Q000627:therapeutic use*; D016174:Hepacivirus; D006526:Hepatitis C / Q000188:drug therapy; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000188:drug therapy*; D012189:Retrospective Studies
D000998:Antiviral Agents; D016898:Interferon-alpha; D015774:Ganciclovir